VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis
USA - NASDAQ:VYGR - US92915B1061 - Common Stock
4.65 USD
+0.1 (+2.2%)
4.71 USD
+0.06 (+1.29%)
Overall VYGR gets a fundamental rating of 2 out of 10. We evaluated VYGR against 534 industry peers in the Biotechnology industry. While VYGR seems to be doing ok healthwise, there are quite some concerns on its profitability. VYGR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year VYGR has reported negative net income.
VYGR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
VYGR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
VYGR's Return On Assets of -33.51% is fine compared to the rest of the industry. VYGR outperforms 63.48% of its industry peers.
VYGR's Return On Equity of -44.25% is fine compared to the rest of the industry. VYGR outperforms 69.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.51% | ||
| ROE | -44.25% | ||
| ROIC | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYGR has more shares outstanding than it did 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.20, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.20, VYGR is in line with its industry, outperforming 58.24% of the companies in the same industry.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.2 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
A Current Ratio of 5.43 indicates that VYGR has no problem at all paying its short term obligations.
VYGR's Current ratio of 5.43 is in line compared to the rest of the industry. VYGR outperforms 59.55% of its industry peers.
A Quick Ratio of 5.43 indicates that VYGR has no problem at all paying its short term obligations.
VYGR has a better Quick ratio (5.43) than 60.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.43 |
3. Growth
3.1 Past
The earnings per share for VYGR have decreased strongly by -760.71% in the last year.
The Revenue for VYGR has decreased by -70.38% in the past year. This is quite bad
The Revenue has been decreasing by -5.18% on average over the past years.
EPS 1Y (TTM)-760.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)-70.38%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-82.42%
3.2 Future
Based on estimates for the next years, VYGR will show a decrease in Earnings Per Share. The EPS will decrease by -4.08% on average per year.
Based on estimates for the next years, VYGR will show a small growth in Revenue. The Revenue will grow by 1.98% on average per year.
EPS Next Y-90.87%
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%
EPS Next 5Y-4.08%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.06%
Revenue Next 5Y1.98%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VYGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VYGR's earnings are expected to decrease with -7.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%
5. Dividend
5.1 Amount
VYGR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.65
+0.1 (+2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners60.07%
Inst Owner Change-0.08%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap257.94M
Revenue(TTM)42.58M
Net Income(TTM)-107934000
Analysts87.78
Price Target15.98 (243.66%)
Short Float %6.32%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.03%
Min EPS beat(2)-15.73%
Max EPS beat(2)-6.33%
EPS beat(4)1
Avg EPS beat(4)-3.62%
Min EPS beat(4)-57.86%
Max EPS beat(4)65.43%
EPS beat(8)5
Avg EPS beat(8)77.88%
EPS beat(12)8
Avg EPS beat(12)94.87%
EPS beat(16)10
Avg EPS beat(16)73.79%
Revenue beat(2)0
Avg Revenue beat(2)-50.87%
Min Revenue beat(2)-53.19%
Max Revenue beat(2)-48.55%
Revenue beat(4)1
Avg Revenue beat(4)-15.39%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)103.06%
Revenue beat(8)5
Avg Revenue beat(8)78.95%
Revenue beat(12)8
Avg Revenue beat(12)106.81%
Revenue beat(16)9
Avg Revenue beat(16)71.86%
PT rev (1m)0%
PT rev (3m)-2.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.1%
EPS NY rev (1m)0%
EPS NY rev (3m)0.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-22.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.06 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.77
BVpS4.4
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.51% | ||
| ROE | -44.25% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 51.54% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.43 | ||
| Altman-Z | -0.2 |
F-Score1
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-760.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y-90.87%
EPS Next 2Y-15.8%
EPS Next 3Y-7.74%
EPS Next 5Y-4.08%
Revenue 1Y (TTM)-70.38%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-82.42%
Revenue Next Year-66.69%
Revenue Next 2Y-16.94%
Revenue Next 3Y-9.06%
Revenue Next 5Y1.98%
EBIT growth 1Y-3109.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-74.77%
EBIT Next 3Y-8.22%
EBIT Next 5Y-16.3%
FCF growth 1Y-226.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-220.52%
OCF growth 3YN/A
OCF growth 5YN/A
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYGR.
Can you provide the valuation status for VOYAGER THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
What is the financial health of VOYAGER THERAPEUTICS INC (VYGR) stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 6 / 10.
What is the earnings growth outlook for VOYAGER THERAPEUTICS INC?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -90.87% in the next year.